A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2018
At a glance
- Drugs BI 836826 (Primary)
- Indications B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Mar 2018 Status changed from active, no longer recruiting to completed.
- 22 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2017 Planned End Date changed from 1 Aug 2017 to 22 Jan 2018.